PledPharma AB Company Announcement PledPharma to present the Phase IIb PLIANT study data at ASCO 2016 Stockholm, 2016-05-19 08:18 CEST (GLOBE NEWSWIRE) -- PledPharma to present the Phase IIb PLIANT study data confirming chemotherapy-induced nerve damage reducing effects of PledOx® at ASCO 2016 PledPharma announced today that it will present the results from the Phase IIb PLIANT clinical study of PledOx® - a potential new drug to reduce nerve damage associated with chemotherapy – at the upcoming ASCO Annual Meeting in Chicago. The data will be presented in a Poster Discussion Session entitled "Patient and Survivor Care", on June 6, 2016 by the study's principal investigator, Professor Bengt Glimelius. "The fact that the results from the PLIANT clinical study have been selected for presentation at ASCO underlines the growing interest that leading oncologists have been showing in PledOx®, which has the potential to reduce the major problem of chemotherapy induced nerve damage," says Jacques Näsström, CEO, PledPharma. "Chemotherapy induced nerve damage can be very troublesome as well as persistent and I look forward to the opportunity to present and discuss, these positive PledOx® results, with leading international oncologists at the upcoming ASCO Annual Meeting in Chicago," says Bengt Glimelius, emeritus professor of oncology at the University of Uppsala and principal investigator of the PLIANT study. In the Phase IIb clinical study, PLIANT patients were treated with PledOx® in order to reduce the risk of nerve damage associated with chemotherapy in advanced colorectal cancer with oxaliplatin. The study results showed a statistically significant and clinically relevant reduction in the incidence and severity of chemotherapy induced peripheral neuropathy compared to placebo. It was also observed that PledOx® does not negatively interfere with the anti-cancer effect of chemotherapy. Symptoms of nerve damage often lead to dose reduction of the chemotherapy or premature discontinuation of therapy. PledPharma’s presentation at the Poster Discussion Session is based on the abstract "Persistent Prevention of CIPN Using Calmangafodipir (PledOx): Results from a Placebo-Controlled Randomized Phase II Study (PLIANT) in Patients with Metastatic Colorectal Cancer (mCRC)", which is available on the ASCO website www.abstracts.asco.org and on www.pledpharma.se. For more information, please contact: Jacques Näsström, CEO, phone: +46 737 130 979 [email protected] Michaela Gertz, CFO, phone: +46 709 26 17 75 [email protected] About PledPharma PledPharma develop new drugs that protect the body against oxidative stress - a potentially disabling and sometimes life-threatening condition that can be caused by chemotherapy and acetaminophen poisoning. The company's most advanced project PledOx® reduces nerve damage associated with chemotherapy. Positive results from phase IIb study PLIANT were presented in the spring of 2015. The drug candidate Aladote® is developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. The project PP-099 aims to limit the damage that occurs to the heart muscle during a heart attack. PledPharma (STO:PLED) is listed on Nasdaq First North. Erik Penser Bank is the Certified Adviser. For further information, please visit www.pledpharma.se
